By
Drug Target Review2025-07-14T13:30:07
Scientists at Lund University have shown that aggressive melanoma tumours are driven by overactive mitochondrial processes – revealing a potential treatment strategy using drugs already approved for other conditions.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2025-09-18T12:00:00
Sponsored by Benchling
2026-05-26T09:05:00
Contributor Thomas Clozel M.D., By Drug Target Review
2024-01-26T13:22:42
Sponsored by bit.bio
2023-01-05T14:41:33
Sponsored by Cell Signaling Technology
2025-06-02T10:00:00
Contributor Professor Stefan Trapp, By Drug Target Review
2026-05-22T07:38:00
Contributor Dr Helen Bright, By Drug Target Review
Site powered by Webvision Cloud